Haloperidol Depot Hikma Farmacêutica (Portugal)

Haloperidol Depot Hikma Farmacêutica is a long‑acting injectable formulation containing haloperidol decanoate, a typical antipsychotic of the butyrophenone class. Marketed in Portugal by Hikma Farmacêutica, the product is supplied as a sterile depot preparation for intramuscular administration, intended for use under medical supervision in the European Union. It is prescribed for the maintenance treatment of chronic psychotic conditions and is classified as a prescription‑only medicine.

Haloperidol Depot Hikma Farmacêutica is indicated for the long‑term management of several psychiatric disorders where sustained dopamine blockade is required.

- Schizophrenia, including maintenance therapy after acute stabilization. - Acute psychotic episodes when oral therapy is not feasible or adherence is a concern. - Manic episodes of bipolar disorder that require antipsychotic control. - Adjunctive treatment in patients with severe agitation or aggression. - Prevention of relapse in patients with a history of recurrent psychosis.

The safety profile of haloperidol decanoate reflects its dopamine‑blocking activity and includes both frequent, mild reactions and less common, potentially serious events.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder. - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability. - Severe hypotension or cardiac arrhythmias.

Clinicians should evaluate patient history and monitor clinical status when initiating haloperidol depot therapy to minimize risks.

- Assess for cardiovascular disease, as haloperidol can affect QT interval. - Review history of movement disorders, including Parkinson’s disease or prior tardive dyskinesia. - Use caution in patients with hepatic or renal impairment; dose adjustments may be required. - Monitor for signs of neuroleptic malignant syndrome, especially during the first weeks of treatment. - Evaluate pregnancy and lactation status; the drug’s safety profile in these conditions is not well established. - Consider potential interactions with other central nervous system depressants.

Haloperidol decanoate may interact with several medications, altering its efficacy or safety.

Avoid: - Concurrent use with other antipsychotics or high‑potency dopamine antagonists, which can increase the risk of extrapyramidal symptoms. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma levels. - QT‑prolonging agents such as certain antiarrhythmics, macrolide antibiotics, or antipsychotics, increasing the risk of cardiac arrhythmias.

Use with caution: - CNS depressants including benzodiazepines, opioids, or alcohol, which may enhance sedation. - Anticholinergic drugs that can mask extrapyramidal side effects. - Medications that affect electrolyte balance (e.g., diuretics) which may predispose to cardiac effects.